LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease

Biochemical Society Transactions

Volumn 40, Issue 5, 2012, Pages 1074-1079

  Xiong, Yulan ^a   Dawson, Valina L ^a,b   Dawson, Ted M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

GTPase; GTPase activating protein (GAP); Guanine nucleotide exchange factor (GEF); Kinase; Leucine rich repeat kinase 2 (LRRK2); Parkinson's disease

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; RAC1 PROTEIN;

AUTOPHAGY; AUTOPHOSPHORYLATION; CRYSTALLIZATION; DIMERIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYDROLYSIS; LEWY BODY; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

GTP PHOSPHOHYDROLASES; HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84866657903     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120093     Document Type: Review

References (54)

1. Lees, A.J., Hardy, J. and Revesz, T. (2009) Parkinson's disease. Lancet 373, 2055-2066
2. Savitt, J.M., Dawson, V.L. and Dawson, T.M. (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116, 1744-1754
3. Martin, I., Dawson, V.L. and Dawson, T.M. (2011) Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 12, 301-325
4. Zimprich, A., Benet-Pages, A., Struhal, W., Graf, E., Eck, S.H., Offman, M.N., Haubenberger, D., Spielberger, S., Schulte, E.C., Lichtner, P. et al. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168-175
5. Chartier-Harlin, M.C., Dachsel, J.C., Vilarino-Guell, C., Lincoln, S.J., Lepretre, F., Hulihan, M.M., Kachergus, J., Milnerwood, A.J., Tapia, L., Song, M.S. et al. (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet. 89, 398-406
6. Vilarino-Guell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J., Soto-Ortolaza, A.I., Cobb, S.A., Wilhoite, G.J., Bacon, J.A. et al. (2011) VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89, 162-167
7. Paisán-Ruíz, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., van der Brug, M., López de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
8. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
9. Mata, I.F., Wedemeyer, W.J., Farrer, M.J., Taylor, J.P. and Gallo, K.A. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286-293
10. Cookson, M.R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 11, 791-797
11. Berwick, D.C. and Harvey, K. (2011) LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol. 21, 257-265
12. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842-16847
13. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232
14. Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.W., Savitt, J.M., Waldvogel, H.J. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60, 557-569
15. Alegre-Abarrategui, J., Christian, H., Lufino, M.M., Mutihac, R., Venda, L.L., Ansorge, O. and Wade-Martins, R. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 18, 4022-4034
16. Dodson, M.W., Zhang, T., Jiang, C., Chen, S. and Guo, M. (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum. Mol. Genet. 21, 1350-1363
17. Biskup, S. and West, A.B. (2009) Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim. Biophys. Acta 1792, 625-633
18. Zabetian, C.P., Samii, A., Mosley, A.D., Roberts, J.W., Leis, B.C., Yearout, D., Raskind, W.H. and Griffith, A. (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65, 741-744
19. Kumari, U. and Tan, E.K. (2009) LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J. 276, 6455-6463
20. Ross, O.A., Spanaki, C., Griffith, A., Lin, C.H., Kachergus, J., Haugarvoll, K., Latsoudis, H., Plaitakis, A., Ferreira, J.J., Sampaio, C. et al. (2009) Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat. Disord. 15, 466-467
21. Seki, N., Takahashi, Y., Tomiyama, H., Rogaeva, E., Murayama, S., Mizuno, Y., Hattori, N., Marras, C., Lang, A.E., George-Hyslop, P.S. et al. (2011) Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. J. Hum. Genet. 56, 671-675
22. Aasly, J.O., Vilarino-Guell, C., Dachsel, J.C., Webber, P.J., West, A.B., Haugarvoll, K., Johansen, K.K., Toft, M., Nutt, J.G., Payami, H. et al. (2010) Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov. Disord. 25, 2156-2163
23. Daniels, V., Vancraenenbroeck, R., Law, B.M., Greggio, E., Lobbestael, E., Gao, F., De Maeyer, M., Cookson, M.R., Harvey, K., Baekelandt, V. and Taymans, J.-M. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem. 116, 304-315
24. Gaig, C., Marti, M.J., Ezquerra, M., Rey, M.J., Cardozo, A. and Tolosa, E. (2007) G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J. Neurol. Neurosurg. Psychiatry 78, 626-628
25. Li, Y., Liu, W., Oo, T.F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826-828
26. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E.N. and Shen, J. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U.S.A. 106, 14622-14627
27. Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M. and Moore, D.J. (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 6, e1000902
28. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380-1388
29. Guo, L., Gandhi, P.N., Wang, W., Petersen, R.B., Wilson-Delfosse, A.L. and Chen, S.G. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 313, 3658-3670
30. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A. and Cookson, M.R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671
31. Li, X., Tan, Y.C., Poulose, S., Olanow, C.W., Huang, X.Y. and Yue, Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103, 238-247
32. Xiong, Y., Yuan, C., Chen, R., Dawson, T.M. and Dawson, V.L. (2012) ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J. Neurosci. 32, 3877-3886
33. Deng, J., Lewis, P.A., Greggio, E., Sluch, E., Beilina, A. and Cookson, M.R. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U.S.A. 105, 1499-1504
34. Lee, B.D., Dawson, V.L. and Dawson, T.M. (2012) Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target for Parkinson's disease. Trends Pharmacol. Sci. 33, 365-373
35. Rudenko, I.N., Chia, R. and Cookson, M.R. (2012) Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med. 10, 20
36. Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A.D., Gerber, S.A., Cuny, G.D. and Glicksman, M.A. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry 50, 9399-9408
37. Weiss, B. (2008) ROCO kinase activity is controlled by internal GTPase function. Sci. Signaling 1, pe27
38. Vigil, D., Cherfils, J., Rossman, K.L. and Der, C.J. (2010) Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10, 842-857
39. Taymans, J.-M., Vancraenenbroeck, R., Ollikainen, P., Beilina, A., Lobbestael, E., De Maeyer, M., Baekelandt, V. and Cookson, M.R. (2011) LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS ONE 6, e23207
40. Gloeckner, C.J., Boldt, K., von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu, H. and Ueffing, M. (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J. Proteome Res. 9, 1738-1745
41. Greggio, E., Taymans, J.-M., Zhen, E.Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V. et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 389, 449-454
42. Kamikawaji, S., Ito, G. and Iwatsubo, T. (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963-10975
43. Webber, P.J., Smith, A.D., Sen, S., Renfrow, M.B., Mobley, J.A. and West, A.B. (2011) Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J. Mol. Biol. 412, 94-110
44. Gasper, R., Meyer, S., Gotthardt, K., Sirajuddin, M. and Wittinghofer, A. (2009) It takes two to tango: regulation of G proteins by dimerization. Nat. Rev. Mol. Cell Biol. 10, 423-429
45. Sen, S., Webber, P.J. and West, A.B. (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem. 284, 36346-36356
46. Ito, G. and Iwatsubo, T. (2012) Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem. J. 441, 987-994
47. Haebig, K., Gloeckner, C.J., Miralles, M.G., Gillardon, F., Schulte, C., Riess, O., Ueffing, M., Biskup, S. and Bonin, M. (2010) ARHGEF7 (β-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS ONE 5, e13762
48. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341
49. Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L., West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers, W.J., Federoff, H.J. et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 16, 998-1000
50. Liu, Z., Hamamichi, S., Lee, B.D., Yang, D., Ray, A., Caldwell, G.A., Caldwell, K.A., Dawson, T.M., Smith, W.W. and Dawson, V.L. (2011) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum. Mol. Genet. 20, 3933-3942
51. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner, S. et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20, 4209-4223
52. Liu, Z., Lee, J., Krummey, S., Lu, W., Cai, H. and Lenardo, M.J. (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 12, 1063-1070
53. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, 3rd, R.J. and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U.S.A. 107, 9879-9884
54. Shutes, A., Onesto, C., Picard, V., Leblond, B., Schweighoffer, F. and Der, C.J. (2007) Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J. Biol. Chem. 282, 35666-35678